| Title |
New developments in the management of advanced melanoma – role of pembrolizumab
|
|---|---|
| Published in |
OncoTargets and therapy, September 2015
|
| DOI | 10.2147/ott.s72823 |
| Pubmed ID | |
| Authors |
Giuseppina Improta, Isabella Leone, Marco Donia, Stefania Gieri, Giuseppe Pelosi, Filippo Fraggetta |
| Abstract |
Cancer immunotherapy is now recognized to be fundamental in modern oncology, because immune system recruitment may represent a powerful and innovative strategy in cancer therapy. Pembrolizumab, a highly selective humanized monoclonal antibody directly blocking the interaction between programmed cell death-1 expressed by tumor-associated T-cells and its ligand programmed cell death-L1 present on tumor and stromal cells, was recently approved by US Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma and disease progression upon ipilimumab and BRAF inhibitor. This review will focus on the clinical development and use of pembrolizumab in the clinical practice and in the management of advanced melanoma. |
Mendeley readers
The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Poland | 1 | 3% |
| Unknown | 39 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 9 | 23% |
| Researcher | 6 | 15% |
| Student > Doctoral Student | 5 | 13% |
| Student > Ph. D. Student | 5 | 13% |
| Student > Bachelor | 4 | 10% |
| Other | 6 | 15% |
| Unknown | 5 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 16 | 40% |
| Agricultural and Biological Sciences | 6 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 10% |
| Biochemistry, Genetics and Molecular Biology | 4 | 10% |
| Immunology and Microbiology | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 6 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 September 2015.
All research outputs
#22,758,309
of 25,373,627 outputs
Outputs from OncoTargets and therapy
#2,078
of 3,016 outputs
Outputs of similar age
#237,474
of 276,788 outputs
Outputs of similar age from OncoTargets and therapy
#61
of 100 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 276,788 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.